Introduction
Afibrinogenemia is defined by undetectable circulatory fibrinogen which can lead to a variety of bleeding and thrombotic complications for affected individuals. 1 The soluble precursor to fibrin, fibrinogen is a conserved hexameric protein with its three polypeptide chains, Aα, Bβ, and γ , encoded by three genes; FGA, FGB and FGG in humans. Minor isoforms of Aα (Aα-E) and γ (γ') arise by differential mRNA splicing. Mutations in one of the fibrinogen genes can cause afibrinogenemia, but causal mutations have been found predominantly in FGA. 2 Afibrinogenemia is rare, affecting about 1 in 10 6 individuals, and can be treated by replacement therapy. However, as with other heritable bleeding disorders, the variable phenotype of afibrinogenemia is not fully understood and an experimental system where genetic and environmental influences on phenotype could be assessed would be a useful research tool.
While targeted disruption of Fga in mice clearly leads to an afibrinogenemia-like phenotype 3 we sought to produce a zebrafish model of afibrinogenemia. The zebrafish (D. rerio) is used as a model vertebrate in developmental biology and for modeling human disease. 4 Coagulation factors have been described in zebrafish, 5 their genes are identifiable in the zebrafish genome, 6 and hemostasis assays have been adapted to the model. 7 With large numbers of offspring and rapid external early development the zebrafish is compatible with genetic or chemical screening approaches, such as searching for phenotypic modifier genes or therapeutic agents. [8] [9] In addition, we anticipated that female zebrafish lacking circulating fibrinogen may not incur the lethality seen in gestating afibrinogenemic mice. 3 We previously characterized the zebrafish fibrinogen genes and their expression during development.
10
Furthermore, a transitory model of low fibrinogen levels in zebrafish larvae was recently reported using antisense morpholino oligonucleotides targeting fibrinogen mRNAs. 11 However, no evidence for lowered fibrinogen protein levels was provided. A zebrafish model of a congenital human bleeding disorder, with a stable genetic change linked to a relevant phenotype, has not been described. Here we present a zebrafish model of congenital afibrinogenemia. We engineered mutations into the zebrafish fga gene that lead to afibrinogenemic fish with a bleeding phenotype.
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Methods

Zebrafish
AB strain zebrafish were maintained at 28 °C, pH 7.5 and 500 µS conductivity. Experimentation was authorized by the local veterinary authority.
fga mutants
Plasmids encoding zinc finger nucleases (ZFN) designed to target the fga gene, were purchased from Sigma-Aldrich. In vitro transcribed mRNA encoding each half of the dimeric zinc finger nuclease were microinjected into early zebrafish embryos. Surviving fish were raised to reproductive age and screened for transmission of mutated fga by PCR-genotyping embryos from natural crosses. The ZFN used targets a sequence overlapping a BceAI restriction site in fga exon 2 (see Figure 1A ). This enabled identification of mutated fga by BceAI digestion of PCR products. Oligonucleotides used were forward: 5'-AATGGCCTATGTTGGCAGAC-3' and reverse: 5'-CAGTGGTTATCAGCTGACAG-3'. BceAI-resistant PCR products were sequenced and two fish transmitting predicted null alleles were crossed with wild type fish and progeny raised and screened for heterozygosity. Heterozygotes were in-crossed. We identified heterozygous animals from this subsequent generation, for each mutation, because one line had transmitted two mutations, presumably from separate ZFN-directed editing events in the founder animal. Heterozygotes for each of the three mutations were confirmed by sequencing cloned genotyping PCR products (pCRII TOPO, Life technologies). Subsequent in-crosses gave wild type, heterozygous and homozygous fish. Zebrafish experimentation was authorized by the local veterinary authority.
Detection of larval bleeding
Bleeding was assessed in three or five day-old larvae using o-dianisidine staining, essentially as described previously, 12 with post-staining fixation.
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Plasma collection and western blotting
Plasma was prepared from adult fish using a described protocol as a guide. 14 Blood was collected into 300 µl of heparin solution (420 IU/ml) after tail sectioning of anaesthetized fish. Samples of dilute plasma were subjected to western blotting. Antibodies were prepared by immunization of rabbits with peptides found in each of the zebrafish fibrinogen chains (Covalab, France). Peptide sequences, their 
RNA isolation and RT-PCR
RNA was isolated from adult liver samples using Trizol reagent (Life technologies) and reverse transcription-PCR performed as described previously, using unchanged oligonucleotides.
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Results and Discussion
Generating fga mutant zebrafish
The fibrinogen hexamer is assembled from three polypeptide chains; severe truncation of one chain is predicted to cause the absence of circulating fibrinogen. Exon 2 of the zebrafish fga gene, encoding fibrinogen Aα (and Aα-E) was targeted for mutation using ZFN technology 15 ( Figure 1A ). Fish subjected to the ZFN were raised and animals transmitting mutations predicted to give null alleles were out-crossed. Three mutation-transmitting lines were maintained ( Figure 1A) . For personal use only. on May 5, 2017. by guest www.bloodjournal.org From in the generation described. Analysis of further generations will determine whether mutation 3 confers modified survival compared to mutations 1 and 2.
A bleeding phenotype
Criteria for a model of human afibrinogenemia include the absence of circulating fibrinogen ( Figure   1B ) and a variable bleeding phenotype. We sporadically observed bleeding in fish from the lines described and suspected catastrophic bleeding events to explain fatalities of mutant fish. Figure 2B-D show examples of unprompted bleeding found in adult mutant fish. Images were taken prior to genotyping. These bleeding events were variable; cephalic ( Figure 2B and 2D) , ocular ( Figure 2B ), and ventral hemorrhaging ( Figure 2C ) are represented. Such incidents were observed in less than 10% of the expected number of mutation 1 and 2 homozygotes. However, if lethal bleeding events explain the under-representation of the -/-genotype in live adult fish, compared to +/+ siblings, such events occurred in approximately 60% of mutation 1 and 2 homozygotes. We did not detect severe bleeding in live mutation 3 homozygous mutants in the generation described, in accordance with our survival data.
We looked for bleeding in 3 and 5 day-old mutant larvae by staining with o-dianisidine to detect heme.
We observed pools of apparent blood extravasation in 3 day-old mutant larvae, but these events were rare and also seen in wild types (see Supplemental data for images and bleeding frequencies). Either larval mutants do not suffer from additional bleeding events compared to wild types, or with the numbers of larvae analyzed we have not detected it in the current study. Our data imply that severe bleeding as a phenotypic end-point for further study will require large numbers of adult or larval afibrinogenemic zebrafish.
In summary, we describe zebrafish lacking circulating fibrinogen, presenting a bleeding phenotype and reduced survival. Unprompted bleeding was rare, but the phenotypic similarity with human congenital afibrinogenemia validates the use of the zebrafish to search for modifier genes or agents that by functional conservation could affect the human disease. Our findings also infer that the zebrafish can be used as a model for other congenital bleeding disorders. 
